Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Buy" from Analysts

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have been given an average recommendation of "Buy" by the nine analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $63.50.

Several equities analysts have weighed in on the company. Wedbush increased their target price on Vera Therapeutics from $30.00 to $38.00 and gave the company a "neutral" rating in a research note on Friday, November 8th. Scotiabank started coverage on shares of Vera Therapeutics in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $60.00 price target on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an "overweight" rating in a report on Tuesday, November 5th. Guggenheim increased their target price on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a report on Monday, October 28th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $107.00 price target on shares of Vera Therapeutics in a research report on Tuesday, October 1st.

Vera Therapeutics Trading Up 0.9 %

Shares of VERA traded up $0.29 on Tuesday, reaching $33.66. 789,500 shares of the company's stock were exchanged, compared to its average volume of 727,556. The business has a 50 day moving average price of $43.73 and a two-hundred day moving average price of $40.99. Vera Therapeutics has a 12 month low of $15.37 and a 12 month high of $51.61. The stock has a market capitalization of $2.13 billion, a P/E ratio of -12.90 and a beta of 1.15. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.21). Research analysts anticipate that Vera Therapeutics will post -2.89 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Beth C. Seidenberg sold 15,000 shares of the stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $48.03, for a total transaction of $720,450.00. Following the completion of the transaction, the director now directly owns 131,553 shares in the company, valued at approximately $6,318,490.59. This trade represents a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total value of $730,450.00. Following the completion of the sale, the chief executive officer now directly owns 143,603 shares in the company, valued at approximately $5,993,989.22. This represents a 10.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 86,875 shares of company stock worth $3,808,631 over the last ninety days. Company insiders own 21.70% of the company's stock.

Institutional Trading of Vera Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. grew its stake in Vera Therapeutics by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company's stock valued at $86,000 after purchasing an additional 350 shares in the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in shares of Vera Therapeutics in the 2nd quarter valued at approximately $135,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Vera Therapeutics in the second quarter valued at $163,000. Quarry LP acquired a new position in Vera Therapeutics during the second quarter worth $235,000. Finally, HighVista Strategies LLC bought a new stake in Vera Therapeutics during the second quarter worth $331,000. Institutional investors own 99.21% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.